CSL Limited (CSL)
ASX · Healthcare · Biotechnology
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CSL key fundamentals
- Price
- AUD 106.79
- Market cap
- $51.14B
- P/E ratio
- 25.3
- P/S ratio
- 2.3
- EPS
- —
- Revenue (TTM)
- $15.43B
- Net margin
- 9.2%
- Return on equity
- 7.6%
- Debt / equity
- 0.67
- Dividend yield
- 3.99%
- 52-week high
- 275.79
- 52-week low
- 90.00
Statement figures as of 2025-06-30. Market data may be delayed.
How does CSL measure against your lens?
FIS measures CSL Limited against nine fundamental criteria — but which ones matter depends on how you invest. Your lens — growth, value, income, conservative, or balanced — is derived from your preferences, and the same company aligns differently through each. Sign up to see which criteria CSL meets through your lens, in plain English.
- P/E Ratio
- P/S Ratio
- Net Profit Margin
- Return on Equity
- Revenue Growth (YoY)
- EPS Growth (YoY)
- Debt / Equity
- Current Ratio
- Dividend Yield
Free 30-day Pro trial. No credit card required.
This page describes CSL Limited's reported financials and the criteria FIS measures. It is not a rating of the company and not a recommendation to buy, hold, or sell any security.